Atakhodjaeva F. A. (1), Tashbaeva U. I. (2)
Cervical cancer remains one of the most common malignancies among women worldwide. Persistent infection with high-risk human papillomavirus (hrHPV) types is the primary etiological factor. Despite the effectiveness of HPV vaccination and cervical screening, the burden of disease remains high, particularly in low- and middle-income countries. The influence of contraceptive methods—especially combined oral contraceptives (COCs) and intrauterine devices (IUDs)—on cervical epithelial health and HPV-related pathology continues to be debated. This study is conducted to evaluate the potential relationship between the use of COCs and IUDs and the occurrence of cervical epithelial and microbiological alterations, including inflammatory and dysplastic changes, in women of reproductive age.
1. Averbach S., Silverberg M.J., Leyden W., Smith-McCune K., Raine-Bennett T., Sawaya G.F. Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer. Contraception. 2018
2. Averbach S.H., Ma Y., Smith-McCune K., Shiboski S., Moscicki A.B. The effect of intrauterine devices on acquisition and clearance of human papillomavirus. Am J Obstet Gynecol. 2017
3. Asthana S., Loke M.L., Falivene J. Oral contraceptive use and risk of cervical cancer – A systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology. 2020;248:225–233.
4. Bruni L., Serrano B., Mena M., Collado J.J., Gómez D., Muñoz J. Human Papillomavirus and Related Diseases in the World: Summary Report 22 October 2021. Barcelona: ICO/IARC Information Centre on HPV and Cancer, 2021.
5. Canfell K. Towards the global elimination of cervical cancer. Papillomavirus Res. 209;8:100170.
6. Castellsague X., Diaz M., Vaccarella S., de Sanjose S., Munoz N., Herrero R. et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011 7. Cortessis V.K., Barrett M., Brown Wade N., Enebish T., Perrigo J.L., Tobin J. et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017
7. Guo C., Zhang Y., Wang S., et al. Association between oral contraceptive use and cervical cancer: evidence from NHANES. Frontiers in Pharmacology. 2024;15:1400667.
8. International Agency for Research on Cancer. Cervical Cancer. Global Cancer Observatory. 2022.
9. Iversen L., Fielding S., Lidegaard Ø., Skovlund C.W., Hannaford P.C. Contemporary use of hormonal contraception and risk of cervical cancer subtypes: nationwide cohort study. Int. J. Cancer. 2021;148(5):1100–1110.
10. Kim K, Park H, Kim H, et al. Association of intrauterine device use with risk of cervical intraepithelial neoplasia and HPV infection: a nationwide cohort study. Sci Rep. 2021;11:21599. doi:10.1038/s41598-021-01086-6
11. Peng Y., Wang X., Feng H., Yan G. Is oral contraceptive use associated with an increased risk of cervical cancer? An evidence-based meta-analysis. Journal of Obstetrics and Gynaecology Research. 2017;43(5):913–922.
12. Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva Ginecol. 2019;71:313–20.
13. Roura E., Travier N., Waterboer T., de Sanjose S., Bosch F.X., Pawlita M. et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoSOne. 2016 [PubMed] [Google Scholar]
14. Skorstengaard M, Lynge E, Napolitano G, et al. Risk of precancerous cervical lesions in women using a hormone-containing intrauterine device and other contraceptives: a register-based cohort study from Denmark. Hum Reprod. 2021;36(7):1796–1807. doi:10.1093/humrep/deab104
15. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2023.
16. WHO. Cervical Cancer 2020.